Clinical Trial Update: Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) [Phase 3]

View source ↗

Summary

Phase 3 trial THRIVE-AA1 evaluating CTP-543 for efficacy and safety in adults with moderate to severe alopecia areata has completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• CTP-543

Snippet

Sponsor: Concert Pharmaceuticals | Conditions: Alopecia Areata | Phase 3 | Status: COMPLETED | Results posted: 2023-05-03